The purpose of this study is to assess the preliminary efficacy of TQB2825 in combination with chemotherapy in subjects with diffuse large B-cell lymphoma.
The subjects voluntarily participate in this study, sign the informed consent form, and have good compliance;
Age ≥18 years (calculated from the date of informed consent);
Eastern Cooperative Oncology Group (ECOG) score 0 ~ 2 points;
Expected survival greater than 12 weeks;
Subjects who had or currently had other malignant tumors within 5 years prior to the first dose;
Previous or current involvement or suspected involvement of the central nervous system by lymphoma;
Failure to recover from adverse reactions to Common Terminology Criteria for Adverse Events version 5.0 (CTCAEv5.0) criteria ≤ grade 1 from previous treatment;
previous use of other antibody drugs targeting CD3 and CD20 at the same time;